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Utility of inflammatory markers to predict adverse outcome 
in acute pancreatitis: A retrospective study in a single 
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Original Article
INTRODUCTION
Acute pancreatitis  (AP) is a common inflammatory 
condition characterised by local and systemic inflammation 
with symptoms ranging from asymptomatic or mild disease 
to severe systemic inflammatory response complicated by 
persistent organ failure and possibly death.[1‑3]
Background/Aim: Acute pancreatitis (AP) is a commonly encountered emergency where early identification 
of complicated cases is important. Inflammatory markers like lymphocyte to monocyte ratio (LMR) and 
neutrophil to lymphocyte ratio (NLR) are simple and readily available markers. In this study, we evaluated 
the utility of these markers in the early identification of patients with complicated AP. 
Patients and Methods: All patients with a diagnosis of AP admitted to the University Medical Center in 
Las Vegas/Nevada between August 2015 and September 2018 were identified using ICD‑10 codes. Medical 
records were reviewed retrospectively. Epidemiological measures and their associated confidence intervals 
were calculated using MedCalc (v. 18). 
Results: The LMR showed a significant difference between groups, with the non‑complicated cases 
consistently higher than the complicated cases but without significant temporal differences. The NLR showed 
a significant difference with a significant temporal relation. Using the bound of the 95% confidence interval 
separating the two groups, LMR <2 was found to be associated with a complicated case and NLR >10.5 
was suggestive of a complicated case. High specificity (85–92%) with low sensitivity (23–69%) was noted; 
hence, these cut points were very good at discerning non‑complicated cases. 
Conclusion: Our data show persistently low LMR that is associated with severe AP and a value of <2.0 
can be used clinically to predict severe AP on admission. It also shows that elevated NLR is associated 
with complicated AP and prolonged hospital stay with a value >10.5 that can be used to predict severe 
complicated AP and to monitor response to treatment over time.
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Therefore, it is crucial to identify patients with increased 
risk of  developing severe disease and start evidence‑based 
intensive care to prevent the development of  severe 
complications and reduce morbidity and mortality.
Several scoring systems have been developed to stratify 
the severity of  AP, but they have their own limitations, 
namely, Ranson’s and Glasgow score require data that are 
not routinely available at presentation and need long time 
to complete. The acute physiology and chronic health 
examination (APACHE‑II) that was developed to be used 
in critical care setting requires multiple parameters that are 
also not available at the time of  presentations. Sequential 
organ failure assessment (SOFA) has been developed but 
is still suitable only in the intensive care setting and not for 
routine use in all patients presenting with AP. Therefore, 
a simplified serum biomarker that is readily available 
on admission with good sensitivity is required for the 
early identification and treatment of  severe AP to lower 
morbidity and mortality.[4‑6]
Neutrophil to lymphocyte ratio (NLR) and lymphocytes to 
monocyte ratio (LMR) have shown values in predicting the 
disease prognosis of  multiple malignancies and systemic 
inflammatory diseases.[7‑10] These parameters are readily 
available upon admission through a simple complete blood 
count. Few studies have looked into using these values to 
predict the disease severity in case of  acute pancreatitis. 
Our study aims to investigate the validity of  using these 
markers in predicting the disease severity and outcome in 
patients with acute pancreatitis, in addition to treatment 
response over the first 48 hours. It also aims to determine 
the optimal cut‑off  value that would allow the early 
recognition of  patients with the tendency to develop severe 
AP of  multiple etiologies.
PATIENTS AND METHODS
This is a retrospective chart review of  patients admitted 
to the academic medical center with a diagnosis of  AP 
between August 2015 and September 2018. Approval from 
IRB and Ethics committee was obtained on November 
5th, 2018. The patients were identified using ICD‑10 
codes. The patients were labeled as either complicated 
or non‑complicated groups based on the hospital 
course and clinical outcome. Different parameters and 
variables were calculated and compared between the two 
groups (complicated vs. non‑complicated) including LMR 
and NLR on admission and at 24 and 48 hours. Using 
revised Atlanta classification, the patients with moderate 
and severe AP were included in the complicated group and 
mild AP in the non‑complicated group. Clinical course and 
outcome were also considered including ICU admission 
and mortality rate.
Descriptive statistics for all variables were calculated 
to determine the mean, SD, and range of  values. In 
addition, the measures of  skewness and kurtosis were 
evaluated to discern potential deviations from normal 
assumptions. Independent‑sample t‑tests were used to 
compare the demographic variables of  age and total 
length‑of‑stay  (LOS). Of  particular interest was the 
potential of  significant differences owing to time and 
complication status. To address this question, RM‑ANOVA 
was utilised. The RM‑ANOVA was developed for a 
within‑between design, with Greenhouse–Geisser 
estimates reported. To assess potential non‑normality, 
both observed data and a rank‑based transformation 
of  the data were employed; the statistical results were 
identical in both cases and, hence, the parametric results 
are provided. As a final analysis, we investigated the 
potential cut‑points of  significant biomarkers for clinical 
use. Cut points were established using the bound of  the 
95% confidence limit separating the complicated cases 
from non‑complicated cases. Using these results, the 
predicted complicated cases were compared to clinically 
known complicated cases in an epidemiological analysis to 
determine the sensitivity, specificity, PPV and NPV, along 
with their Clopper–Pearson or logit confidence intervals. 
Descriptive statistics and models were calculated using 
the SPSS software (IBM; v. 25). Epidemiological measures 
and their associated confidence intervals were calculated 
using MedCalc (v. 18).
RESULTS
The summary statistics for demographic and clinical 
variables for each time period are provided in Table  1. 
The mean age of  patients was not different between the 
complicated and non‑complicated cases (t = 0.26, P = 0.799) 
but the total LOS did differ, with complicated cases 
representing over twice the total LOS as non‑complicated 
cases (t = 8.18, P < 0.001).
The LMR showed a significant difference between the 
groups, with the non‑complicated cases consistently higher 
than the complicated cases (F = 11.34, P = 0.001) and there 
were no significant temporal differences (F = 1.48, P = 0.232) 
[Figure  1]. The NLR showed a significant difference 
between the groups, with the non‑complicated cases 
consistently lower than the complicated cases (F = 23.11, 
P < 0.001). In addition, there was a significant complication 
status‑by‑time interaction  (F  =  3.88, P =  0.040), with 
significant differences notable at both post‑admission 
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days [P  <  0.05; Figure  2]. The RDW showed both a 
significant change through time  (F  =  4.52, P =  0.034) 
and a significant status‑by‑time interaction  (F  =  4.86, 
P =  0.028), resulting in significant overlap between the 
complicated and non‑complicated cases  [Figure 3]. The 
hematocrit measures showed a significant change through 
time (F = 157.95, P < 0.001), but there was no significant 
difference between status [F = 0.57, P = 0.451; Figure 4]. 
Similarly, for platelet counts, there was a significant change 
through time (F = 13.48, P < 0.001), but there was no 
Table 1: Descriptive statistics for demographic and clinical measures
Variable Non-complicated Cases Complicated Cases
n Min Max Mean SD n Min Max Mean SD
Age 198 14.0 87.0 46.5 15.35 41 19.0 74.0 47.1 13.44
ICU LOS 1 2.0 2.0 2.0 25 1.0 22.0 8.3 7.00
Total LOS 193 1.0 13.0 4.1 2.32 39 2.0 51.0 10.6 9.85
Lipase Admission 197 76.0 16341.0 1152.5 1324.15 41 70.0 5000.0 1204.6 943.78
Lipase Day 1 122 13.0 2079.0 527.3 559.97 22 63.0 2079.0 653.1 526.19
Lipase Day 2 102 5.0 1017.0 177.0 183.75 22 10.0 1908.0 424.5 439.04
WBC Admission 198 2.4 28.0 10.8 4.50 41 4.5 28.3 13.8 6.03
WBC Day 1 187 2.2 25.0 9.5 4.08 41 3.4 27.9 12.4 5.72
WBC Day 2 164 1.9 21.7 8.8 3.74 40 3.4 30.8 11.6 5.79
Hematocrit Admission 198 22.2 56.2 42.7 5.77 41 19.9 57.6 43.4 8.64
Hematocrit Day 1 187 9.5 54.1 38.2 5.78 41 23.2 56.3 39.4 8.83
Hematocrit Day 2 165 12.6 48.7 36.2 5.51 40 21.3 48.9 36.3 6.58
Platelets Admission 198 70.0 888.0 230.7 95.61 41 80.0 776.0 247.3 138.86
Platelets Day 1 187 56.0 1600.0 200.9 134.95 41 55.0 542.0 182.9 100.85
Platelets Day 2 165 36.9 1888.0 196.5 164.37 40 37.0 540.0 166.7 97.29
RDW Admission 195 11.4 23.4 14.5 1.75 41 12.4 25.6 15.2 2.55
RDW Day 1 186 11.9 23.9 14.5 1.70 41 12.4 40.3 15.7 4.34
RDW Day 2 165 12.0 24.2 14.5 1.78 40 12.7 166.9 19.4 24.28
Neutrophil Admission 184 44.5 97.0 77.0 11.92 40 53.0 92.0 80.6 8.86
Neutrophil Day 1 131 18.0 92.1 74.6 12.98 34 53.5 95.0 79.7 12.37
Neutrophil Day 2 99 38.0 97.0 71.8 12.75 31 49.7 95.0 79.6 11.62
Lymphocytes Admission 184 1.8 46.8 14.6 9.38 40 2.2 37.7 11.2 7.88
Lymphocytes Day 1 131 1.9 69.5 16.2 10.87 34 1.9 30.0 9.6 8.28
Lymphocytes Day 2 99 0.8 43.1 17.8 10.28 29 1.0 37.8 11.0 9.01
Neutrophil Admission 178 1.3 24.5 8.6 4.33 39 2.4 25.6 11.4 5.55
Neutrophil Day 1 131 18.0 92.1 74.6 12.98 34 53.5 95.0 79.7 12.37
Neutrophil Day 2 99 38.0 97.0 71.8 12.75 31 49.7 95.0 79.6 11.62
ABS Lymphocyte Admission 178 0.2 13.7 1.5 1.41 39 0.2 6.5 1.4 1.21
ABS Lymphocyte Day 1 130 0.2 26.7 1.5 2.32 32 0.2 26.1 1.7 4.48
ABS Lymphocyte Day 2 96 0.3 3.7 1.4 0.64 28 0.2 3.3 1.1 0.68
ABS Monocyte Admission 178 0.1 9.9 0.8 0.98 39 0.3 2.9 1.0 0.49
ABS Monocyte Day 1 130 0.1 15.2 0.8 1.31 32 0.4 6.9 1.1 1.14
ABS Monocyte Day 2 96 0.2 7.0 0.8 0.71 29 0.1 2.9 0.9 0.57
LMR Admission 178 0.2 14.9 2.4 1.84 39 0.2 5.4 1.6 1.14
LMR Day 1 130 0.3 12.0 2.3 1.69 32 0.3 4.5 1.2 0.96
LMR Day 2 65 0.4 8.0 2.4 1.32 22 0.2 9.0 1.5 1.89
NLR Admission 178 0.4 54.0 9.1 9.11 39 1.4 45.0 13.1 11.81
NLR Day 1 130 0.9 47.0 7.9 7.31 31 1.8 51.0 16.5 12.47
NLR Day 2 38 0.9 32.0 5.4 5.61 15 2.5 98.0 23.6 25.67
Figure 1: Estimated marginal means through time for LMR; 95% CI 
are shown
Figure 2: Estimated marginal means through time for NLR; 95% CI 
are shown
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difference between the complication status  [F  =  0.56, 
P = 0.456; Figure 5].
The cut‑points for potential clinical use were investigated 
using the bound of  the 95% confidence interval separating 
admission complicated and non‑complicated cases for the 
two ratios that were found to be significant, namely LMR 
(cut‑point  <2 indicating a complicated case) and NLR 
(cut‑point >10.5 indicating a complicated case). The overall 
sensitivity was low, ranging from 23 to 69%; however, 
the specificity was quite high, ranging from 85 to 92%. 
Hence, these cut points were very good at discerning the 
non‑complicated cases [Table 2].
DISCUSSION
AP usually runs a mild clinical course without complications, 
requiring only short‑term hospitalisation. However, about 
20% of  the patients develop a complicated clinical course. 
These patients may suffer long‑term intensive care 
admission and hospitalisation, and the need for invasive 
interventions with significant mortality rates may occur 
arising mainly from organ failure or infected pancreatic 
necrosis.[11,12]
Haematological inflammatory markers have been widely 
studied as prognostic markers in multiple inflammatory 
and malignant conditions.[8,13‑16]
In this study, we evaluated the role of  different haematological 
markers in predicting the severity of  AP, ICU admission, 
development of  organ failure and mortality rate in 
our medical centre in Southern Nevada. Our goal was 
to validate the value of  using simple, readily available 
parameters on admission to identify high‑risk patients 
with the potential to develop severe disease which will 
generate a higher degree of  clinical suspicion for possible 
complications and allows more aggressive care leading to 
lower mortality rate and medical expenses. Compared to 
conventional prediction scores, these markers are simple, 
easily accessible and immediately available on admission and 
can be used in facilities where other tests are not available. 
The conventional scores such as APACHE II, BISAP and 
Ranson’s criteria require multiple tests and imaging studies.
White cell count (WCC) is a common serum haematological 
test that is routinely done in most medical and surgical 
emergencies. It is already incorporated in many of  the 
current AP scoring systems; however, it is nonspecific and 
cannot help in predicting poor outcome upon admission.[17]
Multiple studies have shown significance in the WCC 
differentials as an indicator to poor prognosis in 
multiple benign inflammatory and malignant conditions. 
Neutrophils, lymphocytes and monocytes are the important 
components of  WCC. Neutrophils induce inflammation 
and tissue destruction in AP via the activation of  a cascade 
of  inflammatory cytokines  (IL‑6, IL‑8, and TNF‑α), 
proteolytic enzymes and oxygen‑free radicals.[18] An 
increase in the neutrophil number corresponds with the 
development of  SIRS and progression to persistent organ 
failure.[17]
Figure 4: Estimated marginal means through time for haematocrit; 
95% CI are shown
Figure 5: Estimated marginal means through time for platelet counts; 
95% CI are shown
Figure 3: Estimated marginal means through time for RDW; 95% CI 
are shown
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Studies have shown that persistent lymphopenia indicates 
poor prognosis and is an independent marker for 
progressive inflammation, bacteremia and sepsis in 
emergency department and critical care unit.[19,20]
In this study, we investigated the role of  multiple 
haematological inflammatory markers including NLR, 
LMR, RDW, platelets count and haematocrit in predicting 
disease prognosis and outcome, mainly persistent organ 
failure and mortality and we compared these parameters 
against each other.
Based on our results, NLR was found to be persistently higher 
in the complicated group compared to non‑complicated 
group which make it a useful tool in differentiating the 
two groups early on admission. Furthermore, the NLR 
showed significant correlation with disease severity over 
time, making it an excellent tool to follow up on patients’ 
prognosis with normalisation of  values in patients with 
favourable prognosis and persistent elevation in those 
with worse prognosis and persistent organ failure. Per our 
results, the calculated cut‑point value for NLR was >10.5 
which indicates a higher risk for complicated case.
LMR was also investigated and found to be significant 
in predicting complicated cases on admission as it shows 
persistent lower values in complicated cases compared to 
non‑complicated cases; however, it did not show significant 
temporal difference between the two groups. This makes 
it an excellent tool to differentiate the two groups upon 
admission but not good for evaluating the prognosis 
overtime. Our calculated cut‑point value for LMR was <2 
which indicates a complicated case.
Red blood cell distribution width (RDW), reported as a part 
of  the complete blood count test, is a quantitative measure 
of  variability in the size of  circulating erythrocytes.[21] A 
prior study done by Senol et al. reported that the RDW on 
admission could be a predictor for mortality in patients with 
AP.[22] Another study showed that RDW was not associated 
with disease severity in AP but can predict persistent organ 
failure which is associated with increased mortality.[23]
Our results showed statistically significant changes in RDW 
with time, but it did show overlap between complicated 
and non‑complicated cases which make its clinical use of  
limited value.
Haematocrit and platelet count were investigated as 
independent prognostic factors to predict disease 
severity and both showed significant change with time 
but no significant difference between complicated and 
non‑complicated cases.
These results show the high value of  using simple, easily 
accessible parameters available immediately on admission 
to identify patients with higher risk of  developing severe 
AP, prolonged hospital stay and higher risk for persistent 
organ failure and mortality which will help in directing 
acute critical care earlier to prevent complications and 
poor outcomes.
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